Immune cell infiltration-based signature for prognosis and immunogenomic analysis in breast cancer

Abstract Breast cancer is one of the most human malignant diseases and the leading cause of cancer-related death in the world. However, the prognostic and therapeutic benefits of breast cancer patients cannot be predicted accurately by the current stratifying system. In this study, an immune-related...

Full description

Saved in:
Bibliographic Details
Published in:Briefings in bioinformatics 2021-03, Vol.22 (2), p.2020-2031
Main Authors: Wang, Shiyuan, Zhang, Qi, Yu, Chunlu, Cao, Yiyin, Zuo, Yongchun, Yang, Lei
Format: Article
Language:English
Subjects:
Biomarkers
Breast cancer
Chemotherapy
Genomics
Genotypes
Immune system
Immunotherapy
Medical prognosis
Meta-analysis
Mutation
Survival
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Breast cancer is one of the most human malignant diseases and the leading cause of cancer-related death in the world. However, the prognostic and therapeutic benefits of breast cancer patients cannot be predicted accurately by the current stratifying system. In this study, an immune-related prognostic score was established in 22 breast cancer cohorts with a total of 6415 samples. An extensive immunogenomic analysis was conducted to explore the relationships between immune score, prognostic significance, infiltrating immune cells, cancer genotypes and potential immune escape mechanisms. Our analysis revealed that this immune score was a promising biomarker for estimating overall survival in breast cancer. This immune score was associated with important immunophenotypic factors, such as immune escape and mutation load. Further analysis revealed that patients with high immune scores exhibited therapeutic benefits from chemotherapy and immunotherapy. Based on these results, we can conclude that this immune score may be a useful tool for overall survival prediction and treatment guidance for patients with breast cancer.
ISSN:1467-5463
1477-4054
DOI:10.1093/bib/bbaa026